Loading
CH
Cue Health Inc. Stock: price and insider trades · United States
Cue Health Inc.: what insiders have been doing
Every trade that managers of Cue Health Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Cue Health Inc. The previous disclosure was published on 27 August 2024.
Since 2021, the database holds no purchases and 39 sales by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
194
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€3M
39 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
Revenue63.1M
Net income-332.5M-526.5% margin
Last declaration on 27 August 2024
Declarations194 total
3,230,779 shares0Common StockSEC:0000902664-24-005276:1
1,067,674 shares0Common StockSEC:0000902664-24-005276:2
3,319,000 shares0Common StockSEC:0000902664-24-005276:3
10,684,791 shares100.0% of flowCommon stock, par value $0.00001 per share ("Common Stock")SEC:0000902664-24-005276:0
20,456 shares@ US$0.190.5% of flowCommon StockSEC:0001628945-24-000052:0
10,742 shares@ US$0.250.3% of flowCommon StockSEC:0001628945-24-000028:0
13,327 shares@ US$0.2516.3% of flowCommon StockSEC:0001628945-24-000032:0
8,482 shares@ US$0.250.3% of flowCommon StockSEC:0001628945-24-000035:0
12,604 shares@ US$0.250.4% of flowCommon StockSEC:0001628945-24-000031:0
7,304 shares@ US$0.2511.3% of flowCommon StockSEC:0001628945-24-000036:0
200,000 shares0Common StockSEC:0001628945-24-000023:1
700,000 shares0Common StockSEC:0001628945-24-000021:0
200,000 shares0Common StockSEC:0001628945-24-000025:0
63,300 shares0Common StockSEC:0001628945-24-000020:0
500,000 shares0Common StockSEC:0001628945-24-000022:0
300,000 shares0Common StockSEC:0001628945-24-000026:0
300,000 shares0Common StockSEC:0001628945-24-000023:0
31,938 shares@ US$0.301.1% of flowCommon StockSEC:0001628945-23-000191:0
25,781 shares@ US$0.301.0% of flowCommon StockSEC:0001628945-23-000192:0
15,885 shares@ US$0.350.7% of flowCommon StockSEC:0001628945-23-000185:0
11,623 shares@ US$0.3519.9% of flowCommon StockSEC:0001628945-23-000188:0
7,465 shares@ US$0.350.4% of flowCommon StockSEC:0001628945-23-000186:0
6,186 shares@ US$0.3513.4% of flowCommon StockSEC:0001628945-23-000184:0
13,722 shares@ US$0.350.6% of flowCommon StockSEC:0001628945-23-000187:0
6,272 shares@ US$0.350.4% of flowCommon StockSEC:0001628945-23-000182:0
25 of 194 declarations
About Cue Health Inc.
Cue Health Inc. is a U.S.-based healthcare technology company listed on the NASDAQ under ticker HLTH and headquartered in San Diego, California, United States. Founded in 2010, the company was built around a molecular point-of-care diagnostics platform intended to bring laboratory-style testing closer to the patient or end user. Its core offering revolved around the Cue system: a connected diagnostic platform combining a portable reader with disposable cartridges designed to deliver rapid test results for selected use cases.
From a business-history perspective, Cue Health became widely known during the COVID-19 period, when demand for at-home and decentralized testing gave the company meaningful visibility. That momentum, however, proved difficult to sustain once pandemic-related demand normalized. The company later faced a much more challenging operating backdrop, including lower demand, workforce reductions, and financial stress. In May 2024, Cue Health announced that it would pursue a Chapter 7 wind-down in the United States, a development that materially changed how the equity story should be assessed.
Read moreShow less
Strategically, Cue Health sits at the intersection of diagnostics, medtech, and digital health. Its competitive proposition was based on fast, decentralized, and connected testing, an area where speed, ease of use, clinical performance, and software integration matter greatly. In practice, however, the company competed against much larger and better-capitalized diagnostic and medical-device players, making scale economics, commercialization efficiency, and sustained demand critical challenges.
For French-speaking investors in France, Belgium, and Switzerland, the key analytical point is that Cue Health should be viewed primarily as a distressed or liquidation-stage situation rather than a conventional growth healthcare stock. Recent filings and corporate announcements should be monitored closely, including SEC disclosures and any Form 4 insider transaction activity when available, because these can provide clues about governance, remaining asset value, and the order of claims during the wind-down process. In this setting, the central question is not market expansion, but value preservation, creditor recovery, and whether any residual value might remain for equity holders after liabilities and liquidation costs are addressed.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
